Pregabalin/riluzole (Neurodawn Pharmaceutical)

普瑞巴林/利鲁唑 (南京宁丹新药技术股份有限公司)

Report date: 2026/04/03 20:03:44

Base Information

Drug NamePregabalin/riluzole (Neurodawn Pharmaceutical)
Drug Alias NameRiluzole/pregabalinY-4
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated calcium channel alpha2/delta subunit 1 blockersSodium channel alpha subunit modulators
TargetsVoltage-gated calcium channel alpha2/delta subunit 1Sodium channel alpha subunit
Therapy Area/IndicationsAnxiety DisordersDepressionNeuralgia, Postherpetic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsYes PregabalinRiluzole
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNeuroDawn Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeuroDawn Pharmaceutical Co LtdYantai Yene Pharma Co Ltd
Inactive CompaniesN/A
Active IndicationsAnxiety DisordersDepressionNeuralgia, Postherpetic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A